The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

NCT06833307 | Not Yet Recruiting Phase 3

• 1 other identifier: SHR-1314-307
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to assess efficacy, safety of subcutaneous SHR-1314 in pediatric patients of age 6 to \<18 years with moderate-to-Severe plaque psoriasis

Conditions

Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis

Outcome Measures

Primary Outcomes (2)

• Safety assessment including adverse events at Week 16

  Week 16

• PK parameters: Cmax at Week 12

  Week 12

Secondary Outcomes (3)

• Percentage of subjects who achieve at least 75% improvement in PASI score (PASI 75) at Week 12

  Week 12

• sPGA of 0 or 1 response at Week 12

  Week 12

• Percentage of subjects who achieve at least 90% improvement in PASI score (PASI 90)at Week 12

  Week 12

Study Arms (1)

SHR-1314

EXPERIMENTAL

Drug: SHR-1314

Interventions

SHR-1314 DRUG

SHR-1314: dose 1 SHR-1314:dose 2 SHR-1314:dose 3

SHR-1314

Eligibility Criteria

• Age: 6 Years - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• between 6 and 18years of age at time of screening.
• Chronic plaque-type psoriasis present for at least 6 months and diagnosed before randomization.
• Moderate to severe psoriasis as defined at Baseline/ randomization by:
• PASI score of 12 or greater, and sPGA score of 3 or greater (based on a static scale of 0 - 5), and Body Surface Area (BSA) affected by plaque psoriasis of 10% or greater.

You may not qualify if:

• Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttate psoriasis) at Screening or Baseline/randomization.
• Drug-induced psoriasis.
• Had a clinically significant flare of psoriasis during the 12 weeks prior to baseline (Week 0).
• Presence of other skin conditions (e.g. skin infections, seborrheic dermatitis) that in the judgement of the Investigator could interfere with assessment of psoriasis.
• History of inflammatory bowel disease or have other ongoing active autoimmune diseases.
• At screening, history or symptoms of malignancy of any organ system, treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
• History of congestive heart failure (New York Heart Association \[NYHA\] functional classification ≥III), cerebro-cardiovascular events, or serious bleeding events at screening and / or randomization that in the judgement of the Investigator prevents the subject from participating in the study.
• Active systemic infections (other than common cold) during the 4 weeks before randomization (e.g., hepatitis), or serious infections requiring hospitalization and/or intravenous injection of antibiotic treatment within eight weeks prior torandomization.
• History of depression and/or suicidal ideation or any suicidal behavior based on an assessment with the Columbina Suicide Severity Rating Scale (C-SSRS) at screening and baseline (Posner K et al, 2011), The subjects will be exluded if any answer to question is "yes" in the questionnaire orare clinically judged by the investigator to be at risk for suicide.
• All subjects will be tested for tuberculosis status using IGRA and X-ray test.
• Have evidence of positive test for hepatitis B, hepatitis C antibody, or human immunodeficiency virus (HIV) antibodies.
• Have a known allergy or hypersensitivity to any biologic therapy at screening that would pose an unacceptable risk to the subject if participating in this study.

Sponsors & Collaborators

• Suzhou Suncadia Biopharmaceuticals Co., Ltd.: lead

Study Sites (2)

Capital Medical University Affiliated Children's Hospital

Beijing, Beijing Municipality, 100045, China

Location

Shanghai Huashan Hospital

Shanghai, Shanghai Municipality, 200040, China

Location

Central Study Contacts

xiaoyan bai

CONTACT

+0518-81220121; xiaoyan.bai@hengrui.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 11, 2025
• First Posted: February 18, 2025
• Study Start: February 1, 2025
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): August 1, 2026
• Last Updated: February 18, 2025

Record last verified: 2025-02

Locations

CN (2)